Galecto, Inc.
GLTO•NASDAQ•Healthcare•Biotechnology

About Galecto

Galecto, Inc., a clinical-stage biotechnology company, develops molecule therapeutics for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company develops GB3226, a preclinical small molecule dual inhibitor of ENL-YEATS and FLT3 and GB1211, an oral small molecule inhibitor of galectin-3 to treat multiple types of oncology and liver disease indications. Galecto, Inc. was founded in 2011 and is headquartered in Copenhagen, Denmark.

Company Information

SectorHealthcare
IndustryBiotechnology
CEOHans Schambye
Founded2011
IPO DateOctober 29, 2020
Employees5
CountryDenmark
Fiscal YearJanuary - December

Stock Details

ExchangeNASDAQ (NASDAQ)
CurrencyUSD - USD
TypeStock

Contact Information

Websitegalecto.com
Phone45 70 70 52 10
Address
Ole Maaloes Vej 3, Copenhagen N Copenhagen, 2200 Denmark

Corporate Identifiers

CIK0001800315
CUSIP36322Q107
ISINUS36322Q2066
EIN37-1957007
SIC2834

Leadership Team & Key Executives

Dr. Hans T. Schambye M.D., Ph.D.
Co-Founder, President, Chief Executive Officer and Director
Lori C. Firmani
Chief Financial Officer
Garrett Winslow Esq.
Senior Vice President, General Counsel and Corporate Secretary
Ulf J. Nilsson Ph.D.
Co-Founder
Dr. Hakon Leffler M.D., Ph.D.
Co-Founder
Prof. Tariq Sethi B.Sc., FRCP, M.A., M.D., Ph.D.
Co-Founder
Matthew Kronmiller
Executive Vice President of Strategy and Chief Business Officer